Market Cap 244.53B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 13.58
Forward PE 12.88
Profit Margin 23.09%
Debt to Equity Ratio 0.77
Volume 1,734,000
Avg Vol 2,139,394
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 99%
Beta 0.60
Analysts Sell
Price Target $118.00

Latest News on NVS

BioNTech says Novartis executive Zapata-Gomez to become CFO

May 5, 2025, 6:34 AM EDT - 4 weeks ago

BioNTech says Novartis executive Zapata-Gomez to become CFO

BNTX


Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 4 weeks ago

Final Trade: NVS, XLU and SMMT

SMMT XLU


Novartis to Acquire Regulus in $1.7 Billion Deal

Apr 30, 2025, 7:50 AM EDT - 4 weeks ago

Novartis to Acquire Regulus in $1.7 Billion Deal

RGLS


Novartis to buy Regulus Therapeutics for up to $1.7 billion

Apr 30, 2025, 7:25 AM EDT - 4 weeks ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

RGLS


Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 2:09 PM EDT - 5 weeks ago

Novartis AG (NVS) Q1 2025 Earnings Call Transcript


Pharma firms maastraz

Apr 29, 2025, 12:06 PM EDT - 5 weeks ago

Pharma firms maastraz

AZN GSK NVO


Novartis Lifts Guidance After Profit, Sales Top Views

Apr 29, 2025, 1:27 AM EDT - 5 weeks ago

Novartis Lifts Guidance After Profit, Sales Top Views


Novartis more upbeat on 2025 guidance after strong Q1 momentum

Apr 29, 2025, 1:12 AM EDT - 5 weeks ago

Novartis more upbeat on 2025 guidance after strong Q1 momentum


Novartis After Sandoz: The Business Without Generics

Apr 6, 2025, 6:38 AM EDT - 2 months ago

Novartis After Sandoz: The Business Without Generics